Overview

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

Status:
Withdrawn

Trial end date:
2002-12-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Colorado, Denver

Collaborator:

National Institute on Drug Abuse (NIDA)

Treatments:

Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone

Criteria

Inclusion Criteria:

Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age,
and have no prior history of drug or alcohol abuse or dependence. Subjects must have had
some minimal experience with opioids (e.g. at least two prior exposures)

Exclusion Criteria:

Individuals with evidence of an active Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,
organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular
disease) or pregnant female subjects are excluded from study participation.